Aldafermin, the Glossary
Aldafermin is a fibroblast growth factor 19 (FGF19) analogue developed for non-alcoholic steatohepatitis.[1]
Table of Contents
2 relations: FGF19, Metabolic dysfunction–associated steatotic liver disease.
- Experimental drugs developed for non-alcoholic fatty liver disease
FGF19
Fibroblast growth factor 19 is a protein that in humans is encoded by the FGF19 gene.
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a type of chronic liver disease.
See Aldafermin and Metabolic dysfunction–associated steatotic liver disease
See also
Experimental drugs developed for non-alcoholic fatty liver disease
- ARO-HSD
- AXA1125
- AZD2693
- Aldafermin
- Azemiglitazone
- Belapectin
- DA-1241
- Denifanstat
- EDP-305
- Efruxifermin
- HEC96719
- HU6
- Lanifibranor
- Lipogenesis inhibitor
- Obeticholic acid
- PXL065
- Rencofilstat
- Seladelpar
- Selvigaltin
- Semaglutide
- TERN-501
- Tipelukast
- VK2809
- ZSP1601